Liberum Capital reissued their hold rating on shares of AstraZeneca (LON:AZN) in a research note released on Wednesday, ThisIsMoney.Co.Uk reports.

Other equities research analysts have also issued research reports about the company. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Deutsche Bank reissued a buy rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Friday, July 26th. Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Jefferies Financial Group cut their target price on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a hold rating on the stock in a research report on Friday, May 24th. Finally, Barclays raised their target price on AstraZeneca from GBX 7,500 ($98.00) to GBX 7,600 ($99.31) and gave the stock an overweight rating in a research report on Friday, July 26th. Three analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 6,658.82 ($87.01).

AZN stock opened at GBX 7,351 ($96.05) on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The firm has a market cap of $96.44 billion and a price-to-earnings ratio of 42.94. The firm has a 50-day moving average of GBX 6,645.92. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,349.30 ($96.03).

The company also recently declared a dividend, which will be paid on Monday, September 9th. Shareholders of record on Thursday, August 8th will be given a dividend of GBX 71.90 ($0.94) per share. This represents a yield of 1.07%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What is a Stop Order?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.